California's Tandem Diabetes plans to offer more than 8.2 million shares of stock at a maximum of $15 apiece for an initial public offering of up to $123.2 million. Tandem Diabetes Care upped the ante on its venture-backed initial public offering, increasing its maximum aggregate price to $123.2 million and pricing shares at between $13-$15 apiece. The company, maker of the touch-screen t:slim insulin delivery system, will begin trading on the Nasdaq exchange under the ticker 'TNDM' following the IPO.
Help employers find you! Check out all the jobs and post your resume.
